Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

Fig. 1

Expression of CXCR4 receptor in CLL-B, normal B, T, and stroma-NK-tert cells. a CXCR4 expression was assessed by surface staining using an anti-CXCR4 antibody in CLL-B, normal B, T, and stroma-NK-tert cells. A representative panel is shown. b CXCR4 expression was evaluated by flow cytometry in CLL patient cells with high-risk and low-risk characteristics (n = 20 per group) and in normal B and T cells obtained from healthy donors (n = 5 per group). The figure shows the mean fluorescence intensities (MFI) ± standard deviation (SD) of the samples analyzed in duplicate for CXCR4 expression in each cell type. Statistical significance was determined by using Bonferroni’s correction test for multiple comparison tests, where *, **, ***, and **** represent p < 0.05; p < 0.01, p < 0.001, and p < 0.0001, respectively

Back to article page